Drugs / BPB-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05869240 | May 2023 → Aug 2025 | cancer | Betta Pharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-12-05 | Betta Pharmaceuticals Co., Ltd. | Results 2025 ESMO Asia丨BPB-101在晚期实体瘤患者中的Ia期剂量递增研究成果入选口头报告 bettapharma.com ↗
中山大学肿瘤防治中心马宇翔教授在会上口头报告了贝达药业靶向GARP/TGF-β复合物及PD-L1的三功能双特异性抗体BPB-101在局部晚期或转移性实体瘤患者中的I期临床研究结果。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-12-05 | Betta Pharmaceuticals Co., Ltd. | 2025 ESMO Asia丨BPB-101在晚期实体瘤患者中的Ia期剂量递增研究成果入选口头报告 bettapharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BPB-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05869240 ↗ |
| Route | Intravenous | “Subjects will receive an intravenous infusion of BPB-101” NCT05869240 ↗ |